Global Benign Prostatic Hyperplasia (BPH) Medication Market Research Report 2022

Publisher Name :
Date: 03-Aug-2022
No. of pages: 118
Inquire Before Buying

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

- 5-Alpha-Reductase Inhibitors

- Beta-Blockers

- Botanicals and Traditional Chinese Medicine

Segment by Application

- Hospital Pharmacies

- Retail Pharmacies

- Online Pharmacies

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

By Company

- Astellas Pharma

- Eli Lilly

- GlaxoSmithKline

- Sanofi

- ADC Therapeutics

- Bayer HealthCare

- Bristol-Myers Squibb

- Valeant Pharmaceuticals

- Endo Pharmaceuticals

- Foresee Pharmaceuticals

- Merck

- Novartis

- Advaxis

- Teva Pharmaceutical Industries

- Urologixs

- Agennix

- ANI Pharmaceuticals

- BHR Pharma

- Boehringer Ingelheim

- Sanpower Group

- Eisai

- Ferring

- IO THERAPEUTICS

- LIDDS

- Madrigal Pharmaceuticals

- Nymox Pharmaceutical

- Spectrum Pharmaceuticals

- Takeda Pharmaceuticals

Global Benign Prostatic Hyperplasia (BPH) Medication Market Research Report 2022

Table of Contents
1 Benign Prostatic Hyperplasia (BPH) Medication Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Medication
1.2 Benign Prostatic Hyperplasia (BPH) Medication Segment by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 5-Alpha-Reductase Inhibitors
1.2.3 Beta-Blockers
1.2.4 Botanicals and Traditional Chinese Medicine
1.3 Benign Prostatic Hyperplasia (BPH) Medication Segment by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Comparison by Application: (2022-2028)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Estimates and Forecasts
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue 2017-2028
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales 2017-2028
1.4.3 Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region: 2017 Versus 2021 Versus 2028
2 Benign Prostatic Hyperplasia (BPH) Medication Market Competition by Manufacturers
2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Manufacturers (2017-2022)
2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Sites, Area Served, Product Type
2.5 Benign Prostatic Hyperplasia (BPH) Medication Market Competitive Situation and Trends
2.5.1 Benign Prostatic Hyperplasia (BPH) Medication Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Benign Prostatic Hyperplasia (BPH) Medication Players Market Share by Revenue
2.5.3 Global Benign Prostatic Hyperplasia (BPH) Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Benign Prostatic Hyperplasia (BPH) Medication Retrospective Market Scenario by Region
3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Country
3.3.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
3.3.2 North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Country
3.4.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
3.4.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Region
3.5.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Region
3.5.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Country
3.6.1 Latin America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
3.6.2 Latin America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Country
3.7.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
3.7.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Benign Prostatic Hyperplasia (BPH) Medication Historic Market Analysis by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2017-2022)
4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Type (2017-2022)
4.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Type (2017-2022)
5 Global Benign Prostatic Hyperplasia (BPH) Medication Historic Market Analysis by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2017-2022)
5.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application (2017-2022)
5.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Astellas Pharma
6.1.1 Astellas Pharma Corporation Information
6.1.2 Astellas Pharma Description and Business Overview
6.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.1.5 Astellas Pharma Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Corporation Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Corporation Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.3.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 ADC Therapeutics
6.5.1 ADC Therapeutics Corporation Information
6.5.2 ADC Therapeutics Description and Business Overview
6.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.5.4 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.5.5 ADC Therapeutics Recent Developments/Updates
6.6 Bayer HealthCare
6.6.1 Bayer HealthCare Corporation Information
6.6.2 Bayer HealthCare Description and Business Overview
6.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.6.5 Bayer HealthCare Recent Developments/Updates
6.7 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.7.5 Bristol-Myers Squibb Recent Developments/Updates
6.8 Valeant Pharmaceuticals
6.8.1 Valeant Pharmaceuticals Corporation Information
6.8.2 Valeant Pharmaceuticals Description and Business Overview
6.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.8.5 Valeant Pharmaceuticals Recent Developments/Updates
6.9 Endo Pharmaceuticals
6.9.1 Endo Pharmaceuticals Corporation Information
6.9.2 Endo Pharmaceuticals Description and Business Overview
6.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.9.5 Endo Pharmaceuticals Recent Developments/Updates
6.10 Foresee Pharmaceuticals
6.10.1 Foresee Pharmaceuticals Corporation Information
6.10.2 Foresee Pharmaceuticals Description and Business Overview
6.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.10.5 Foresee Pharmaceuticals Recent Developments/Updates
6.11 Merck
6.11.1 Merck Corporation Information
6.11.2 Merck Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Merck Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.11.5 Merck Recent Developments/Updates
6.12 Novartis
6.12.1 Novartis Corporation Information
6.12.2 Novartis Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.12.3 Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Novartis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.12.5 Novartis Recent Developments/Updates
6.13 Advaxis
6.13.1 Advaxis Corporation Information
6.13.2 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.13.3 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.13.5 Advaxis Recent Developments/Updates
6.14 Teva Pharmaceutical Industries
6.14.1 Teva Pharmaceutical Industries Corporation Information
6.14.2 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.14.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.14.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.15 Urologixs
6.15.1 Urologixs Corporation Information
6.15.2 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.15.3 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.15.5 Urologixs Recent Developments/Updates
6.16 Agennix
6.16.1 Agennix Corporation Information
6.16.2 Agennix Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.16.3 Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Agennix Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.16.5 Agennix Recent Developments/Updates
6.17 ANI Pharmaceuticals
6.17.1 ANI Pharmaceuticals Corporation Information
6.17.2 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.17.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.17.4 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.17.5 ANI Pharmaceuticals Recent Developments/Updates
6.18 BHR Pharma
6.18.1 BHR Pharma Corporation Information
6.18.2 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.18.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.18.4 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.18.5 BHR Pharma Recent Developments/Updates
6.19 Boehringer Ingelheim
6.19.1 Boehringer Ingelheim Corporation Information
6.19.2 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.19.3 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.19.5 Boehringer Ingelheim Recent Developments/Updates
6.20 Sanpower Group
6.20.1 Sanpower Group Corporation Information
6.20.2 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.20.3 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.20.4 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.20.5 Sanpower Group Recent Developments/Updates
6.21 Eisai
6.21.1 Eisai Corporation Information
6.21.2 Eisai Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.21.3 Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.21.4 Eisai Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.21.5 Eisai Recent Developments/Updates
6.22 Ferring
6.22.1 Ferring Corporation Information
6.22.2 Ferring Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.22.3 Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.22.4 Ferring Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.22.5 Ferring Recent Developments/Updates
6.23 IO THERAPEUTICS
6.23.1 IO THERAPEUTICS Corporation Information
6.23.2 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.23.3 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.23.4 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.23.5 IO THERAPEUTICS Recent Developments/Updates
6.24 LIDDS
6.24.1 LIDDS Corporation Information
6.24.2 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.24.3 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.24.4 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.24.5 LIDDS Recent Developments/Updates
6.25 Madrigal Pharmaceuticals
6.25.1 Madrigal Pharmaceuticals Corporation Information
6.25.2 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.25.3 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.25.4 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.25.5 Madrigal Pharmaceuticals Recent Developments/Updates
6.26 Nymox Pharmaceutical
6.26.1 Nymox Pharmaceutical Corporation Information
6.26.2 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.26.3 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.26.4 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.26.5 Nymox Pharmaceutical Recent Developments/Updates
6.27 Spectrum Pharmaceuticals
6.27.1 Spectrum Pharmaceuticals Corporation Information
6.27.2 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.27.3 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.27.4 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.27.5 Spectrum Pharmaceuticals Recent Developments/Updates
6.28 Takeda Pharmaceuticals
6.28.1 Takeda Pharmaceuticals Corporation Information
6.28.2 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.28.3 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2017-2022)
6.28.4 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.28.5 Takeda Pharmaceuticals Recent Developments/Updates
7 Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Cost Analysis
7.1 Benign Prostatic Hyperplasia (BPH) Medication Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Medication
7.4 Benign Prostatic Hyperplasia (BPH) Medication Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Benign Prostatic Hyperplasia (BPH) Medication Distributors List
8.3 Benign Prostatic Hyperplasia (BPH) Medication Customers
9 Benign Prostatic Hyperplasia (BPH) Medication Market Dynamics
9.1 Benign Prostatic Hyperplasia (BPH) Medication Industry Trends
9.2 Benign Prostatic Hyperplasia (BPH) Medication Market Drivers
9.3 Benign Prostatic Hyperplasia (BPH) Medication Market Challenges
9.4 Benign Prostatic Hyperplasia (BPH) Medication Market Restraints
10 Global Market Forecast
10.1 Benign Prostatic Hyperplasia (BPH) Medication Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Medication by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Medication by Type (2023-2028)
10.2 Benign Prostatic Hyperplasia (BPH) Medication Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Medication by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Medication by Application (2023-2028)
10.3 Benign Prostatic Hyperplasia (BPH) Medication Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Medication by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Medication by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Growth Rate Comparison by Type (2022-2028) & (KG) & (US$ Million)
Table 2. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Growth Rate Comparison by Application (2022-2028) & (KG) & (US$ Million)
Table 3. Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Benign Prostatic Hyperplasia (BPH) Medication Market Competitive Situation by Manufacturers in 2021
Table 5. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) of Key Manufacturers (2017-2022)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Benign Prostatic Hyperplasia (BPH) Medication Average Price (USD/KG) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Sites and Area Served
Table 11. Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Medication by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Medication as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2017-2022) & (KG)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2017-2022)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2017-2022)
Table 19. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2017-2022) & (KG)
Table 20. North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2017-2022)
Table 21. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2017-2022)
Table 23. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2017-2022) & (KG)
Table 24. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2017-2022)
Table 25. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2017-2022) & (KG)
Table 28. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2017-2022)
Table 31. Latin America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2017-2022) & (KG)
Table 32. Latin America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2017-2022)
Table 33. Latin America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2017-2022) & (KG)
Table 36. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2017-2022)
Table 39. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2017-2022) & (KG)
Table 40. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2017-2022)
Table 41. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Type (2017-2022)
Table 43. Global Benign Prostatic Hyperplasia (BPH) Medication Price by Type (2017-2022) & (USD/KG)
Table 44. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Application (2017-2022)
Table 45. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2017-2022)
Table 46. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Application (2017-2022)
Table 48. Global Benign Prostatic Hyperplasia (BPH) Medication Price by Application (2017-2022) & (USD/KG)
Table 49. Astellas Pharma Corporation Information
Table 50. Astellas Pharma Description and Business Overview
Table 51. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 52. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product
Table 53. Astellas Pharma Recent Developments/Updates
Table 54. Eli Lilly Corporation Information
Table 55. Eli Lilly Description and Business Overview
Table 56. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 57. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product
Table 58. Eli Lilly Recent Developments/Updates
Table 59. GlaxoSmithKline Corporation Information
Table 60. GlaxoSmithKline Description and Business Overview
Table 61. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 62. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product
Table 63. GlaxoSmithKline Recent Developments/Updates
Table 64. Sanofi Corporation Information
Table 65. Sanofi Description and Business Overview
Table 66. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 67. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product
Table 68. Sanofi Recent Developments/Updates
Table 69. ADC Therapeutics Corporation Information
Table 70. ADC Therapeutics Description and Business Overview
Table 71. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 72. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product
Table 73. ADC Therapeutics Recent Developments/Updates
Table 74. Bayer HealthCare Corporation Information
Table 75. Bayer HealthCare Description and Business Overview
Table 76. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 77. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product
Table 78. Bayer HealthCare Recent Developments/Updates
Table 79. Bristol-Myers Squibb Corporation Information
Table 80. Bristol-Myers Squibb Description and Business Overview
Table 81. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 82. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product
Table 83. Bristol-Myers Squibb Recent Developments/Updates
Table 84. Valeant Pharmaceuticals Corporation Information
Table 85. Valeant Pharmaceuticals Description and Business Overview
Table 86. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 87. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 88. Valeant Pharmaceuticals Recent Developments/Updates
Table 89. Endo Pharmaceuticals Corporation Information
Table 90. Endo Pharmaceuticals Description and Business Overview
Table 91. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 92. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 93. Endo Pharmaceuticals Recent Developments/Updates
Table 94. Foresee Pharmaceuticals Corporation Information
Table 95. Foresee Pharmaceuticals Description and Business Overview
Table 96. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 97. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 98. Foresee Pharmaceuticals Recent Developments/Updates
Table 99. Merck Corporation Information
Table 100. Merck Description and Business Overview
Table 101. Merck Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 102. Merck Benign Prostatic Hyperplasia (BPH) Medication Product
Table 103. Merck Recent Developments/Updates
Table 104. Novartis Corporation Information
Table 105. Novartis Description and Business Overview
Table 106. Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 107. Novartis Benign Prostatic Hyperplasia (BPH) Medication Product
Table 108. Novartis Recent Developments/Updates
Table 109. Advaxis Corporation Information
Table 110. Advaxis Description and Business Overview
Table 111. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 112. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product
Table 113. Advaxis Recent Developments/Updates
Table 114. Teva Pharmaceutical Industries Corporation Information
Table 115. Teva Pharmaceutical Industries Description and Business Overview
Table 116. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 117. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product
Table 118. Teva Pharmaceutical Industries Recent Developments/Updates
Table 119. Urologixs Corporation Information
Table 120. Urologixs Description and Business Overview
Table 121. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 122. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product
Table 123. Urologixs Recent Developments/Updates
Table 124. Agennix Corporation Information
Table 125. Agennix Description and Business Overview
Table 126. Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 127. Agennix Benign Prostatic Hyperplasia (BPH) Medication Product
Table 128. Agennix Recent Developments/Updates
Table 129. ANI Pharmaceuticals Corporation Information
Table 130. ANI Pharmaceuticals Description and Business Over
  • Global Scar Treatment Oils Market Research Report 2022
    Published: 12-Aug-2022        Price: US 2900 Onwards        Pages: 93
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Natural - Synthetic Segment by Application - Hospitals - Dermatology Clinics ......
  • Global Injection Anesthetic Drugs Market Research Report 2022
    Published: 12-Aug-2022        Price: US 2900 Onwards        Pages: 98
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - General Anesthesia Drugs - Local Anesthesia Drugs Segment by Application - Cosmetic Surgery......
  • Global Opioid Pain Patche Market Research Report 2022
    Published: 12-Aug-2022        Price: US 2900 Onwards        Pages: 93
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Opioid Patches - Non-opioid Patches Segment by Application - Hospital Pharmacies - Re......
  • Global Pain Patches Market Research Report 2022
    Published: 12-Aug-2022        Price: US 2900 Onwards        Pages: 98
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Buprenorphine - Fentanyl Segment by Application - Hospital Pharmacies - Retail Pharma......
  • Global Skin Antiseptic Market Research Report 2022
    Published: 12-Aug-2022        Price: US 2900 Onwards        Pages: 96
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Alcohol - Chlorhexidine and other diguanide - Quaternary ammonium compound - Halogenated phenol deri......
  • Global Hair Thickener Serum Market Research Report 2022
    Published: 12-Aug-2022        Price: US 2900 Onwards        Pages: 98
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Organic - Conventional Segment by Application - Men - Women - Unisex ......
  • Global Patient Cleansing Products Market Research Report 2022
    Published: 12-Aug-2022        Price: US 2900 Onwards        Pages: 100
    Patient Cleansing Products market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Patient Cleansing Products market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - Hand & Body Care - Facial Care Segment by Applic......
  • Global Depression-MDD Drugs Market Research Report 2022
    Published: 12-Aug-2022        Price: US 2900 Onwards        Pages: 85
    Depression-MDD Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Depression-MDD Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - Selective Serotonin Reuptake Inhibitors, - Serotonin & Norepinephrine Reupt......
  • Global Long-Term Asthma Drugs Market Research Report 2022
    Published: 12-Aug-2022        Price: US 2900 Onwards        Pages: 85
    Long-Term Asthma Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Long-Term Asthma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - Tablet - Spray Segment by Application - Hospital ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs